Biweekly irinotecan plus bolus 5-Fluorouracil and folinic acid in patients with advanced stage colorectal cancer

Japanese Journal of Clinical Oncology

Volumn 33, Issue 11, 2003, Pages 580-583

  Yalcin, Suayib ^a   Oksuzoglu, Berna ^a   Tekuzman, Gülten ^a   Engin, Hüseyin ^a   Celik, Ismail ^a   Turker, Alev ^a   Barista, Ibrahim ^a   Gullu, Ibrahim ^a   Guler, Nilufer ^a   Altundag, Kadri ^a   Ozisik, Yavuz ^a   Kars, Ayse ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

5 fluorouracil; Advanced colorectal cancer; Folinic acid; Irinotecan

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; IRINOTECAN; LEVAMISOLE; LOPERAMIDE; ONDANSETRON; TROPISETRON; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BOLUS INJECTION; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL ADENOMA; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INOPERABLE CANCER; LEUKOCYTE COUNT; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPHIL; OVARY METASTASIS; PERITONEUM METASTASIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ADENOCARCINOMA; COLON TUMOR; DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; RECTUM TUMOR; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; RECTAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 1342289079     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg111     Document Type: Article

References (24)

1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;55:891-903.
2. Burkitt DP. Epidemiology of cancer of the colon and rectum. Dis Colon Rectum 1993;30:1071-82.
3. Wingo PA, Tong T, Bolden S. Cancer Statistics 1995. CA Cancer J Clin 1995;45:8-30.
4. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivate in metastatic colorectal cancer. J Clin Oncol 1993;11:909-13.
5. Sasaki Y, Ohtsu A, Shimida Yono K, Saijo N. Simultaneous administration of CPT-11 and fluorouracil: Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994;86:1096-8.
6. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48 Geneva: Worid Health Organization, 1979.
7. NCI-NIH National Cancer Institute-National Institute of Health. Common Toxicity Criteria, version 2.0. NCI-NIH Bethesda/MD, 1999;1-80.
8. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Star Assoc 1958;53:457-81.
9. Cox DR, Oakes D. Analysis of survival data, London: Chapman and Hall 1994.
10. Norusis MJ. SPSS for Windows Base System User's Guide Release 6.0., First edition, SPSS Inc., Chicago, 1993.
11. Gallo RC, Whang-Peng J, Adamson RH. Studies on the antitumour activity, mechanism of action and cell cycle effects of camptothecin. J Natl Cancer Inst 1971;46:789-95.
12. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato H. Intracellular roles of SN-38, a metabolite of the camptothecin derivated CPT-11, in the antitumour effect of CPT-11. Cancer Res 1991;51:4187-91.
13. Gotlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. Preliminary pharmacological and clinic evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 1970;54:461-70.
14. Armand JP, Extra YM, Catimel G, Abierges D, Marty M, Clavel M. Rationale for the dosage and schedule of CPT-11 (Irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 1996;7:837-42.
15. Canal P, Gay C, Dezeuze A, Douilliard JY, Bugat R, Brunet R, et al. Pharmacokinetics and pharmacodynamics of irinotecan hydrochloride (CPT-11) during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996;14:2688-95.
16. Rothenberg ML, Kuhn JG, Burris HA 3rd, Nelson, J, Echardt JR, TristanMorales M, et al. Phase I and pharmacokinetie trial of weekly CPT-11. J Clin Oncol 1993;11:2194-204.
17. Abirgerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-21.
18. Conti JA, Kemeny N, Saltz LB, Huang Y, Tong WP, Chou TC, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709-15.
19. Pitot HC, Wender DB, O'Connel MJ, Schroder G, Goldberg RM, Rubin J, et al. Phase II trial of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 1997;15:2910-9.
20. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
21. Karaoglu A, Yalcin S, Tekuzman G, Kars A, Celik I, Guler N, et al. Weekly irinotecan in patients with metastatic colorectal cancer failing to 5-fluorouracil based chemotherapy: Efficacy and prognostic factors. Tumori 2003;89(2):141-5.
22. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 2001;19:1501-18.
23. Yalcin S, Güler N, Kansu E, Ertenli I, Gullu I, Kars A, et al. Granulocyte colony stimulating factor (G-CSF) administration for chemotherapyinduced neutropenia. Hematology 1996;1:155-62.
24. Yalcin S, Tekuzman G, Baltali E, Ozisik Y, Barista I. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic single-day chemotherapy: A randomized study. Am J Clin Oncol 1999;22:94-6.